{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=41",
    "query": {
      "intervention": "Formulation #1",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 1760,
    "total_pages": 176,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T22:59:49.408Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03438461",
      "title": "A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Seltorexant 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Seltorexant 20 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 49,
      "start_date": "2018-02-09",
      "completion_date": "2018-05-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-11-05T22:59:49.408Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03438461"
    },
    {
      "nct_id": "NCT05287360",
      "title": "A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Rivoceranib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-12-30",
      "completion_date": "2022-03-24",
      "has_results": false,
      "last_update_posted_date": "2022-04-18",
      "last_synced_at": "2026-11-05T22:59:49.408Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05287360"
    },
    {
      "nct_id": "NCT00990613",
      "title": "A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Huntington's Disease"
      ],
      "interventions": [
        {
          "name": "Dimebon IR",
          "type": "DRUG"
        },
        {
          "name": "Dimebon Transdermal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 19,
      "start_date": "2009-10",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2010-02-03",
      "last_synced_at": "2026-11-05T22:59:49.408Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00990613"
    },
    {
      "nct_id": "NCT03456713",
      "title": "A Study of LY3074828 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "LY3074828",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 72,
      "start_date": "2018-03-06",
      "completion_date": "2018-08-13",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-11-05T22:59:49.408Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03456713"
    },
    {
      "nct_id": "NCT01443442",
      "title": "Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "bepotastine besilate, 1.5%",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol etabonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southern California College of Optometry at Marshall B. Ketchum University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2011-10",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-11-05T22:59:49.408Z",
      "location_count": 2,
      "location_summary": "Fullerton, California",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01443442"
    },
    {
      "nct_id": "NCT00533741",
      "title": "SARS Coronavirus Vaccine (SARS-CoV)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Coronavirus (SARS-CoV)"
      ],
      "interventions": [
        {
          "name": "Aluminum hydroxide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SARS-CoV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-12-03",
      "last_synced_at": "2026-11-05T22:59:49.408Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00533741"
    },
    {
      "nct_id": "NCT06204679",
      "title": "Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer Study"
      ],
      "interventions": [
        {
          "name": "Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions",
          "type": "DRUG"
        },
        {
          "name": "Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions",
          "type": "DRUG"
        },
        {
          "name": "Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atea Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 42,
      "start_date": "2023-12-14",
      "completion_date": "2024-08-25",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-05T22:59:49.408Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06204679"
    },
    {
      "nct_id": "NCT00551031",
      "title": "Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza",
        "Myxovirus Infection"
      ],
      "interventions": [
        {
          "name": "Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Split, Inactivated, Trivalent Influenza Vaccine (High-dose)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2098,
      "start_date": "2007-10",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2016-05-16",
      "last_synced_at": "2026-11-05T22:59:49.408Z",
      "location_count": 29,
      "location_summary": "Alabaster, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00551031"
    },
    {
      "nct_id": "NCT00967811",
      "title": "A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Formulation E1 of L-PPDS",
          "type": "DRUG"
        },
        {
          "name": "Formulation E2 of L-PPDS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2009-08",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2013-09-19",
      "last_synced_at": "2026-11-05T22:59:49.408Z",
      "location_count": 1,
      "location_summary": "Menlo Park, California",
      "locations": [
        {
          "city": "Menlo Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00967811"
    },
    {
      "nct_id": "NCT02510794",
      "title": "Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2015-09-28",
      "completion_date": "2019-03-28",
      "has_results": true,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-11-05T22:59:49.408Z",
      "location_count": 50,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Encino, California + 43 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02510794"
    }
  ]
}